Fampridine Market Top Leading Players with Strategies and Forecast 2027
The global fampridine market is expected to grow at a significant CAGR during the forecast period (2021-2027). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, to remain competitive in the marketplace. For instance, Bojian Company announced in May, 2021 that Fampridine Sustained-Release Tablets have been approved by the National Medical Products Administration, China, for the treatment of multiple sclerosis (MS) in adult patients with a walking disorder. Fampridine sustained-release pills are the first medication for adult MS patients in China to enhance their walking capacity. The first batch of clinically urgently needed international new medications includes fampridine sustained-release pills.
The National Medical Products
Administration accepted its new medication marketing application in January
2021, and it was included in the priority review and approval procedure in
April 2021. Three global phase 3 randomized, double-blind, placebo-controlled
trials were mentioned in the National Medical Products Administration's drug
review. The results showed that patients who were given fampridine
sustained-release pills had much faster walking speeds than those who were
given a placebo. Furthermore, Fampridine Sustained-Release Tablets have a quick
therapeutic reaction time, with the curative impact appearing few weeks after
the treatment begins. MS was added to the "First List of Rare
Diseases" in May 2018. According to the data published by the National MS
Society of Canada in September 2020, 2.8 million people across the globe have
multiple sclerosis (MS). That implies someone with MS is diagnosed every 5
minutes somewhere on the planet. The majority of people with MS are diagnosed
between the ages of 20 and 50, and women are three times more likely than males
to have the disease. This, in turn, is accelerating the growth of the global
fampridine market.
To Request a Sample of our Report on Fampridine Market: https://www.omrglobal.com/request-sample/fampridine-market
Moreover, in December 2018, Hikma
Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp.,
launched Dalfampridine Extended-release Tablets, 10 mg, the generic
pharmaceutical equivalent to Ampyra, according to Hikma Pharmaceuticals PLC.
Dalfampridine Extended-release Tablets are used to support adults with multiple
sclerosis improve their walking by increasing their walking pace. Hikma was one
of the first ANDA applicants to submit a paragraph IV certification disputing
the validity of patents mentioned for Ampyra tablets, 10 mg, and is thus
entitled for 180 days of generic medication exclusivity. Hikma was one of two
generic producers who failed not reach an agreement with Acorda Therapeutics
among the ten first-filers. According to Acorda Therapeutics' 2017 annual
report, Ampyra sales in the US accounted for $543 million in 2017, up 10% from
2016.
Market Coverage
• The market number
available for – 2020-2027
• Base year- 2020
• Forecast period-
2021-2027
Segment Covered-
·
By Product
·
By Form
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape:
Biogen Inc., Acorda Therapeutics, Inc., and Hikma Pharmaceuticals plc, among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Fampridine Market is Available @ https://www.omrglobal.com/industry-reports/fampridine-market
Global Fampridine Market Report by Segment
By Type
• Purity: 95%
• Purity: >95%
By Form
• Branded
• Generic
Global Fampridine Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment